Biocon Limited (BOM:532523)
India
· Delayed Price · Currency is INR | Market Cap | 499.34B |
| Revenue (ttm) | 152.62B |
| Net Income (ttm) | 10.13B |
| Shares Out | n/a |
| EPS (ttm) | 8.46 |
| PE Ratio | 49.28 |
| Forward PE | 63.21 |
| Dividend | 0.50 (0.13%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 150,088 |
| Average Volume | 207,776 |
| Open | 372.40 |
| Previous Close | 372.40 |
| Day's Range | 372.05 - 377.45 |
| 52-Week Range | 290.80 - 404.60 |
| Beta | n/a |
| RSI | 64.40 |
| Earnings Date | Jul 30, 2025 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2024, Biocon's revenue was 152.62 billion, an increase of 3.43% compared to the previous year's 147.56 billion. Earnings were 10.13 billion, a decrease of -0.90%.
Financial StatementsNews
Biocon to announce Q1 FY26 results on August 7
Biocon Limited has informed stock exchanges that its Board of Directors will meet on Thursday, August 7, 2025, to approve and take on record the unaudited standalone and consolidated financial results...
It’s wrong to blame Covid jabs for cardiac arrests: Biocon chief Kiran Mazumdar-Shaw
Bengaluru: Days after chief minister Siddaramaiah blamed Covid-19 vaccines for the alarming rise in cardiac arrest cases among youngsters in the recen.
'Caution Not Anti-Science': Siddaramaiah On Covid Vaccine-Sudden Death Claim
Karnataka Chief Minister Siddaramaiah has responded to Biocon Ltd Executive Chairperson Kiran Mazumdar-Shaw's suggestion that he acknowledge the science behind vaccine development, rather than engage ...
Biocon Chief Counters Siddaramaiah's Covid Vaccine-Heart Attack Link Claim
Biocon chief Kiran Mazumdar-Shaw has pushed back against Karnataka Chief Minister Siddaramaiah's recent claim that COVID-19 vaccines may be linked to a surge in sudden cardiac deaths in Hassan distric...
Biocon Biologics gets marketing authorisation from EC for Denosumab Biosimilars Vevzuo and Evfraxy
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a leading global biosimilars company, has received marketing authorisation from the European Commission (EC) for its biosimilars Vevzuo® and ...
India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on...
Biocon subsidiary gets Health Canada nod for YESAFILI
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., has received a Notice of Compliance from Health Canada for YESAFILI™ (aflibercept), marking a significant milestone in the company’s global bi...
Biocon shares in focus as company reportedly plans to launch QIP to raise up to Rs 4,500 crore
Biocon Ltd is reportedly preparing to launch a Qualified Institutional Placement (QIP) to raise as much as ₹4,500 crore, possibly as early as this week, according to a Moneycontrol report. As per the ...
Biocon launches BioWISE program to empower women in STEM across Karnataka
Biocon Foundation, the CSR arm of Biocon Group, has announced the launch of its new BioWISE (Women in STEM Empowered) program in partnership with the National Centre for Biological Sciences (NCBS) and...
Top stocks to watch today, June 3: HCLTech, Mphasis, Britannia Industries, Torrent Power, Biocon and more
As Dalal Street opens for trade on Tuesday, June 3, market participants will focus on specific stocks driven by recent announcements, corporate developments, and macroeconomic cues. The previous sessi...
Stocks to watch on June 3: Biocon, PTC India Financial, HCL Tech, Yes Bank, Maruti, Reliance Infra, Aptus Value, Zinka Logistics, Adani Group in focus
Indian equities are set to open with a host of stock-specific triggers on June 3, with several companies announcing business developments, regulatory updates, and block deals. Positive developments Bi...
Biocon receives CDSCO approval for its Liraglutide drug in India
Biocon Limited, a global biopharmaceutical company, has announced that it has received regulatory approval in India for its Liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limit...
‘Metro Mentor’ moment: Kiran Mazumdar-Shaw ditches car, hops on Bengaluru Metro with Exxon Mobil’s ‘Iron Lady’; calls ride ‘quick way to avoid traffic’
Biocon founder Kiran Mazumdar-Shaw opted for the Namma Metro's Purple Line to bypass Bengaluru's notorious traffic, traveling from Whitefield to Vidhana Soudha. She lauded the Bangalore Metro Rail Cor...
Biocon Biologics receives UK MHRA approval for YESINTEK, Biosimilar Ustekinumab
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for YESINTEK®, a bio...
Biocon subsidiary and Yoshindo expand access to Ustekinumab Biosimilar in Japan
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Sub...
Stocks to watch on May 16: Websol, Godrej Industries, Crompton, Biocon, RVNL, Lupin, BLS in focus after Q4 earnings and updates
Several companies are in focus following their quarterly earnings announcements and corporate disclosures. From sharp turnarounds in profits to regulatory approvals and strategic expansions, here’s a ...
JP Morgan, Goldman Sachs & more: Top stocks on brokers' radar for today
Brokerage firms have varying outlooks on Indian companies. JP Morgan is underweight on Dr. Reddy's due to margin concerns, while Citigroup maintains a buy rating on Biocon despite weak numbers. Nomura...
Biocon share price falls today – Should you buy, hold or sell? Check what brokerages say
Shares of Biocon Ltd declined 0.33% to ₹328.80 on Monday despite bullish brokerage commentary and upside estimates of up to 30%. The stock, which closed at ₹329.90 in the previous session, saw muted i...
Stocks to watch on May 9: Titan, BPCL, L&T, Biocon, MCX among key movers in trade today
Equity markets will be tracking a range of corporate announcements and quarterly earnings today. Several major companies across sectors have reported their March quarter results, while others have ann...
Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore
Biocon Limited reported a strong financial performance for the quarter and financial year ended March 31, 2025. For Q4FY25, consolidated revenue came in at Rs 4,454 crore, marking a 12% year-on-year (...
Stocks in focus: Asian Paints, Titan, LT, Britannia, Biocon among key firms to announce Q4 results today
On May 8, 2025, several prominent Indian companies are scheduled to release their financial results for the fourth quarter of fiscal year 2025. The list includes a diverse set of firms across various ...
Biocon share price jumps 4% after its subsidiary receives multiple market access agreements for Yesintek
Biocon shares jumped 4% in early trade after the company announced that its subsidiary, Biologics, had significant U.S. market access agreements for its biosimilar Yesintek™ (ustekinumab-kfce). As of ...
Biocon Biologics secures US market access for Yesintek
Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd., has announced that its biosimilar Yesintek™ (ustekinumab-kfce), approved by the U.S. Food and Drug Administrati...
Biocon shares jump over 2% after EU panel’s positive nod for denosumab biosimilars
Shares of Biocon Ltd rose 2.07% to ₹318.30 in early trade on April 28, 2025, after its subsidiary received a major boost from European regulators. The Committee for Medicinal Products for Human Use (C...
Biocon to raise Rs 4,500 crore via QIP or other routes
Biocon Limited has announced that its board of directors has approved a proposal to raise up to ₹4,500 crore through a mix of instruments, including equity shares, convertible securities, non-converti...